HomeESPR • NASDAQ
Esperion Therapeutics Inc
add
$1.23
4.65%
After Hours:(0.81%)+0.0100
$1.24
Closed: Apr 4, 8:00:00 PM UTC-4 · USD · NASDAQ · Disclaimer
In the news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | 69.11M | 114.30% |
Operating expense | 36.93M | -18.71% |
Net income | -21.32M | 62.16% |
Net profit margin | -30.85 | 82.34% |
Earnings per share | -0.10 | 79.74% |
EBITDA | -4.39M | 89.63% |
Effective tax rate | — | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 144.76M | 76.01% |
Total assets | 343.82M | 67.07% |
Total liabilities | 732.54M | 10.86% |
Total equity | -388.72M | — |
Shares outstanding | 197.85M | — |
Price to book | -0.65 | — |
Return on assets | -3.36% | — |
Return on capital | -5.64% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | -21.32M | 62.16% |
Cash from operations | -34.95M | 5.68% |
Cash from investing | 0.00 | — |
Cash from financing | 35.00M | 682.73% |
Net change in cash | 44.00K | 100.14% |
Free cash flow | -24.72M | 13.40% |
Previous close
$1.29
Day range
$1.17 - $1.30
Year range
$1.17 - $3.94
Market cap
243.35M USD
Avg Volume
4.27M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
About
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan. Wikipedia
Founded
May 1998
Website
Employees
304
